| 2.3 -0.34 (-12.88%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.22 |
1-year : | 8.44 |
| Resists | First : | 5.32 |
Second : | 7.23 |
| Pivot price | 3.76 |
|||
| Supports | First : | 2.25 |
Second : | 1.87 |
| MAs | MA(5) : | 2.73 |
MA(20) : | 4.34 |
| MA(100) : | 6.81 |
MA(250) : | 6.27 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 4.9  |
| RSI | RSI(14): 20.3 |
|||
| 52-week | High : | 24.22 | Low : | 2.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADVB ] has closed above bottom band by 11.6%. Bollinger Bands are 21.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.82 - 2.84 | 2.84 - 2.86 |
| Low: | 2.21 - 2.23 | 2.23 - 2.25 |
| Close: | 2.27 - 2.31 | 2.31 - 2.33 |
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
Wed, 22 Jul 2026
ADVB Stock Spikes On Volatility As Traders Lock In - StocksToTrade
Mon, 20 Jul 2026
Why Is Penny Stock Advanced Biomed (ADVB) Up Today? - TipRanks
Fri, 17 Jul 2026
Advanced Biomed Terminates $25M Equity Purchase Pact With Helena Global Investment Opportunities I - TradingView
Wed, 18 Feb 2026
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation - Yahoo Finance
Fri, 07 Mar 2025
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering - Yahoo Finance
Thu, 06 Mar 2025
Advanced Biomed Inc. Common Stock (ADVB) Historical Data - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | -12 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.65e+006 (%) |
| Held by Institutions | 677080 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 127640 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5 |
| Profit Margin | 5 % |
| Operating Margin | 231.3 % |
| Return on Assets (ttm) | -3 % |
| Return on Equity (ttm) | 856.4 % |
| Qtrly Rev. Growth | -79.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.79 |
| Qtrly Earnings Growth | -6.17e+006 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.46 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 18900 |
| Forward Dividend | 16360 |
| Dividend Yield | 821739% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|